Limits...
Immunohistochemical analysis of CXCR4 expression in fibrohistiocytic tumors.

Toyozawa S, Yamamoto Y, Ishida Y, Kondo T, Nakamura Y, Furukawa F - Acta Histochem Cytochem (2010)

Bottom Line: These receptors promote tumor growth and metastasis in response to endogenous chemokines.Moreover, MFH had strong immunoreactivity for CXCR4, CCR6 and CCR7.These findings suggest that the assessment of CXCR4 immunoreactivity in fibrohistiocytic tumors is a useful tool for predicting tumor aggressiveness.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Wakayama Medical University, Wakayama, Japan. seikotoy@wakayama-med.ac.jp

ABSTRACT
Functional chemokine receptors are expressed in many malignant tumors. These receptors promote tumor growth and metastasis in response to endogenous chemokines. We analyzed the expression of CXCR4, CCR6 and CCR7 in fibrohistiocytic tumors, including dermatofibrosarcoma protuberance (DFSP), malignant fibrous histiocytoma (MFH), dermatofibroma (DF) using immunohistochemistry. We also investigated the relationship between CXCR4 and CD34, the latter of which is an immunohistochemical marker for DFSP. We observed a higher expression of CXCR4 in DFSP and MFH as compared with DF. Interestingly, a significantly higher expression of CXCR4 was detected in relapsed DFSP than in non-relapsed DFSP, but no significant differences were detected between non-relapsed DFSP and DFSP with CD34 immunostaining. Moreover, MFH had strong immunoreactivity for CXCR4, CCR6 and CCR7. These findings suggest that the assessment of CXCR4 immunoreactivity in fibrohistiocytic tumors is a useful tool for predicting tumor aggressiveness.

No MeSH data available.


Related in: MedlinePlus

CXCR4 immunoexpression in fibrohistiocytic tumors (×200). A. No expression of CXCR4 was observed in non-relapsed DFSP. B. Diffuse CXCR4 expression was observed in relapsed DFSP. C. Diffuse CXCR4 expression was observed in MFH. D. No expression of CXCR4 was observed in DF.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2875858&req=5

Figure 1: CXCR4 immunoexpression in fibrohistiocytic tumors (×200). A. No expression of CXCR4 was observed in non-relapsed DFSP. B. Diffuse CXCR4 expression was observed in relapsed DFSP. C. Diffuse CXCR4 expression was observed in MFH. D. No expression of CXCR4 was observed in DF.

Mentions: Representative results of the immunohistochemical staining for CXCR4 are shown in Figure 1. CXCR4 immunoexpression was detected in 8/8 (100%) cases of DFSP, 6/6 cases (100%) of MFH, 12/14 (86%) cases of DF. As shown in Figure 2, the average scores of the CXCR4 immunostaining were significantly higher in DFSP and MFH as compared with DF (p<0.01). Moreover, CXCR4 immunoexpression was significantly higher in relapsed DFSP as compared with non-relapsed DFSP (p<0.01). However, there was no difference in immunostaining intensity between the two DFSP groups.


Immunohistochemical analysis of CXCR4 expression in fibrohistiocytic tumors.

Toyozawa S, Yamamoto Y, Ishida Y, Kondo T, Nakamura Y, Furukawa F - Acta Histochem Cytochem (2010)

CXCR4 immunoexpression in fibrohistiocytic tumors (×200). A. No expression of CXCR4 was observed in non-relapsed DFSP. B. Diffuse CXCR4 expression was observed in relapsed DFSP. C. Diffuse CXCR4 expression was observed in MFH. D. No expression of CXCR4 was observed in DF.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2875858&req=5

Figure 1: CXCR4 immunoexpression in fibrohistiocytic tumors (×200). A. No expression of CXCR4 was observed in non-relapsed DFSP. B. Diffuse CXCR4 expression was observed in relapsed DFSP. C. Diffuse CXCR4 expression was observed in MFH. D. No expression of CXCR4 was observed in DF.
Mentions: Representative results of the immunohistochemical staining for CXCR4 are shown in Figure 1. CXCR4 immunoexpression was detected in 8/8 (100%) cases of DFSP, 6/6 cases (100%) of MFH, 12/14 (86%) cases of DF. As shown in Figure 2, the average scores of the CXCR4 immunostaining were significantly higher in DFSP and MFH as compared with DF (p<0.01). Moreover, CXCR4 immunoexpression was significantly higher in relapsed DFSP as compared with non-relapsed DFSP (p<0.01). However, there was no difference in immunostaining intensity between the two DFSP groups.

Bottom Line: These receptors promote tumor growth and metastasis in response to endogenous chemokines.Moreover, MFH had strong immunoreactivity for CXCR4, CCR6 and CCR7.These findings suggest that the assessment of CXCR4 immunoreactivity in fibrohistiocytic tumors is a useful tool for predicting tumor aggressiveness.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Wakayama Medical University, Wakayama, Japan. seikotoy@wakayama-med.ac.jp

ABSTRACT
Functional chemokine receptors are expressed in many malignant tumors. These receptors promote tumor growth and metastasis in response to endogenous chemokines. We analyzed the expression of CXCR4, CCR6 and CCR7 in fibrohistiocytic tumors, including dermatofibrosarcoma protuberance (DFSP), malignant fibrous histiocytoma (MFH), dermatofibroma (DF) using immunohistochemistry. We also investigated the relationship between CXCR4 and CD34, the latter of which is an immunohistochemical marker for DFSP. We observed a higher expression of CXCR4 in DFSP and MFH as compared with DF. Interestingly, a significantly higher expression of CXCR4 was detected in relapsed DFSP than in non-relapsed DFSP, but no significant differences were detected between non-relapsed DFSP and DFSP with CD34 immunostaining. Moreover, MFH had strong immunoreactivity for CXCR4, CCR6 and CCR7. These findings suggest that the assessment of CXCR4 immunoreactivity in fibrohistiocytic tumors is a useful tool for predicting tumor aggressiveness.

No MeSH data available.


Related in: MedlinePlus